<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02878837</url>
  </required_header>
  <id_info>
    <org_study_id>IAMSPE</org_study_id>
    <nct_id>NCT02878837</nct_id>
  </id_info>
  <brief_title>Dexmedetomidine vs Midazolam for Intraoperative Sedation</brief_title>
  <official_title>Dex vs Dazzle: Dexmedetomidine vs Midazolam for Intraoperative Sedation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto de Assistencia Medica ao Servidor Publico Estadual, Sao Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto de Assistencia Medica ao Servidor Publico Estadual, Sao Paulo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized, open clinical trial sought to compare the use of Midazolam and
      Dexmedetomidine during surgery in patients under regional anesthesia.

      The primary objective was to determine the superiority of either drug during the
      intraoperative period regarding: 1- Depth of sedation and 2- incidence of complications.

      Secondary objectives included the determination of superiority regarding the postoperative
      period.

      For that, patients were randomized into two groups and sedated with either Midazolam or
      Dexmedetomidine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study was a randomized, open clinical trial.

      Patients undergoing surgery under regional (neuraxial or brachial plexus block) anesthesia
      were randomly assigned into one of two groups.

      Patients in one of the groups (called MDZ) were initially sedated with a 0.05mg/Kg bolus dose
      of Midazolam.

      The ones in the other group (called DEX) were initially sedated with a loading dose of 1
      µg/Kg of Dexmedetomidine over 10 minutes, followed by continuous infusion at 0.2 to 0.8
      µg/Kg/h.

      In order to achieve a Richmond Agitation-Sedation Scale (RASS) score between -3 and -1, the
      following breakthrough doses were used as necessary:

      MDZ: 0.02 mg/Kg bolus dose of Midazolam plus 0.5µg/Kg bolus dose of Fentanyl DEX: 0.5µg/Kg
      bolus dose of Fentanyl

      Depth of sedation and incidence of complications were recorded during surgery, in the Post
      Anesthesia Care Unit (PACU) and in the Ward for two days following surgery,
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Actual">May 2017</completion_date>
  <primary_completion_date type="Actual">April 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Depth of Sedation</measure>
    <time_frame>Intraoperative</time_frame>
    <description>Number of breakthrough doses necessary to achieve RASS score between -3 and -1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Respiratory depression</measure>
    <time_frame>Intraoperative</time_frame>
    <description>Use of supplemental oxygen flow greater than 2L/min or endotracheal intubation for mechanical ventilation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bradycardia</measure>
    <time_frame>Intraoperative</time_frame>
    <description>Heart Rate &lt; 50 heartbeats per minute</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hypotension</measure>
    <time_frame>Intraoperative</time_frame>
    <description>Mean Arterial Pressure &lt; 55mmHg</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Residual Sedation</measure>
    <time_frame>Up to 2 hours after surgery</time_frame>
    <description>RASS score &lt; -1 in Post Anesthesia Care Unit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Shivering</measure>
    <time_frame>Up to 2 hours after end of surgery</time_frame>
    <description>Self-described by the patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain</measure>
    <time_frame>2 days</time_frame>
    <description>Pain, described by the patient, according to the Analog Scale. Necessity of breakthrough doses of analgesics.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Sleep</measure>
    <time_frame>2 days</time_frame>
    <description>Self-described.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delirium</measure>
    <time_frame>2 days</time_frame>
    <description>Incidence of Delirium according to CAM-ICU algorithm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Hospital Stay</measure>
    <time_frame>Until Discharge, up to 30 days</time_frame>
    <description>Length of time between surgery and discharge from Hospital, in days</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Failed Moderate Sedation During Procedure</condition>
  <condition>Minimally Conscious State</condition>
  <arm_group>
    <arm_group_label>DEX</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients undergoing surgical procedures under regional anesthesia sedated with a loading dose of 1 µg/Kg of Dexmedetomidine over 10 minutes followed by continuous infusion at 0.2 to 0.8 µg/Kg/h, along with 0.5µg/Kg bolus breakthrough doses of Fentanyl as necessary to achieve a RASS score between -3 and -1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MDZ</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients undergoing surgical procedures under regional anesthesia sedated with a 0.05mg/Kg bolus dose of Midazolam, along with 0.02 mg/Kg bolus doses of Midazolam plus 0.5µg/Kg bolus doses of Fentanyl as necessary to achieve a RASS score between -3 and -1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <arm_group_label>DEX</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <arm_group_label>MDZ</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Undergoing surgery under regional anesthesia

        Exclusion Criteria:

          -  The presence of any Bradyarrhythmia;

          -  New York Heart Association (NYHA) Functional Classes III and IV Heart Failure and/or
             Left Ventricle Ejection Fraction under 30%;

          -  Respiratory Failure, Glasgow Coma Scale score 8 or under, and Liver Failure - due to
             the increased risk of sedation in patients with these conditions (d) refusal to
             participate in the study or withdrawal of consent at any moment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital do Servidor Publico Estadual</name>
      <address>
        <city>Sao Paulo</city>
        <state>Sao Paulo SP</state>
        <zip>04039-901</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Ostermann ME, Keenan SP, Seiferling RA, Sibbald WJ. Sedation in the intensive care unit: a systematic review. JAMA. 2000 Mar 15;283(11):1451-9. Review.</citation>
    <PMID>10732935</PMID>
  </reference>
  <reference>
    <citation>Bailey PL, Pace NL, Ashburn MA, Moll JW, East KA, Stanley TH. Frequent hypoxemia and apnea after sedation with midazolam and fentanyl. Anesthesiology. 1990 Nov;73(5):826-30.</citation>
    <PMID>2122773</PMID>
  </reference>
  <reference>
    <citation>American Society of Anesthesiologists Task Force on Sedation and Analgesia by Non-Anesthesiologists. Practice guidelines for sedation and analgesia by non-anesthesiologists. Anesthesiology. 2002 Apr;96(4):1004-17.</citation>
    <PMID>11964611</PMID>
  </reference>
  <reference>
    <citation>Candiotti KA, Bergese SD, Bokesch PM, Feldman MA, Wisemandle W, Bekker AY; MAC Study Group. Monitored anesthesia care with dexmedetomidine: a prospective, randomized, double-blind, multicenter trial. Anesth Analg. 2010 Jan 1;110(1):47-56. doi: 10.1213/ane.0b013e3181ae0856. Epub 2009 Aug 27.</citation>
    <PMID>19713256</PMID>
  </reference>
  <reference>
    <citation>Hall JE, Uhrich TD, Barney JA, Arain SR, Ebert TJ. Sedative, amnestic, and analgesic properties of small-dose dexmedetomidine infusions. Anesth Analg. 2000 Mar;90(3):699-705.</citation>
    <PMID>10702460</PMID>
  </reference>
  <reference>
    <citation>Ebert TJ, Hall JE, Barney JA, Uhrich TD, Colinco MD. The effects of increasing plasma concentrations of dexmedetomidine in humans. Anesthesiology. 2000 Aug;93(2):382-94.</citation>
    <PMID>10910487</PMID>
  </reference>
  <reference>
    <citation>Venn RM, Hell J, Grounds RM. Respiratory effects of dexmedetomidine in the surgical patient requiring intensive care. Crit Care. 2000;4(5):302-8. Epub 2000 Jul 31.</citation>
    <PMID>11056756</PMID>
  </reference>
  <reference>
    <citation>Arain SR, Ebert TJ. The efficacy, side effects, and recovery characteristics of dexmedetomidine versus propofol when used for intraoperative sedation. Anesth Analg. 2002 Aug;95(2):461-6, table of contents.</citation>
    <PMID>12145072</PMID>
  </reference>
  <reference>
    <citation>Venn RM, Grounds RM. Comparison between dexmedetomidine and propofol for sedation in the intensive care unit: patient and clinician perceptions. Br J Anaesth. 2001 Nov;87(5):684-90.</citation>
    <PMID>11878517</PMID>
  </reference>
  <reference>
    <citation>Elbaradie S, El Mahalawy FH, Solyman AH. Dexmedetomidine vs. propofol for short-term sedation of postoperative mechanically ventilated patients. J Egypt Natl Canc Inst. 2004 Sep;16(3):153-8.</citation>
    <PMID>15959548</PMID>
  </reference>
  <reference>
    <citation>Abdalla MI, Al Mansouri F, Bener A. Dexmedetomidine during local anesthesia. J Anesth. 2006;20(1):54-6.</citation>
    <PMID>16421680</PMID>
  </reference>
  <reference>
    <citation>Taghinia AH, Shapiro FE, Slavin SA. Dexmedetomidine in aesthetic facial surgery: improving anesthetic safety and efficacy. Plast Reconstr Surg. 2008 Jan;121(1):269-76. doi: 10.1097/01.prs.0000293867.05857.90.</citation>
    <PMID>18176230</PMID>
  </reference>
  <reference>
    <citation>Usta B, Gozdemir M, Demircioglu RI, Muslu B, Sert H, Yaldiz A. Dexmedetomidine for the prevention of shivering during spinal anesthesia. Clinics (Sao Paulo). 2011;66(7):1187-91.</citation>
    <PMID>21876972</PMID>
  </reference>
  <reference>
    <citation>Bajwa SJ, Gupta S, Kaur J, Singh A, Parmar S. Reduction in the incidence of shivering with perioperative dexmedetomidine: A randomized prospective study. J Anaesthesiol Clin Pharmacol. 2012 Jan;28(1):86-91. doi: 10.4103/0970-9185.92452.</citation>
    <PMID>22345953</PMID>
  </reference>
  <reference>
    <citation>Belleville JP, Ward DS, Bloor BC, Maze M. Effects of intravenous dexmedetomidine in humans. I. Sedation, ventilation, and metabolic rate. Anesthesiology. 1992 Dec;77(6):1125-33.</citation>
    <PMID>1361310</PMID>
  </reference>
  <reference>
    <citation>Takrouri MS, Seraj MA, Channa AB, el-Dawlatly AA, Thallage A, Riad W, Khalaf M. Dexmedetomidine in intensive care unit: a study of hemodynamic changes. Middle East J Anaesthesiol. 2002 Oct;16(6):587-95.</citation>
    <PMID>12503262</PMID>
  </reference>
  <results_reference>
    <citation>Gertler R, Brown HC, Mitchell DH, Silvius EN. Dexmedetomidine: a novel sedative-analgesic agent. Proc (Bayl Univ Med Cent). 2001 Jan;14(1):13-21.</citation>
    <PMID>16369581</PMID>
  </results_reference>
  <results_reference>
    <citation>Gerlach AT, Murphy CV. Dexmedetomidine-associated bradycardia progressing to pulseless electrical activity: case report and review of the literature. Pharmacotherapy. 2009 Dec;29(12):1492. doi: 10.1592/phco.29.12.1492.</citation>
    <PMID>19947809</PMID>
  </results_reference>
  <results_reference>
    <citation>Riker RR, Shehabi Y, Bokesch PM, Ceraso D, Wisemandle W, Koura F, Whitten P, Margolis BD, Byrne DW, Ely EW, Rocha MG; SEDCOM (Safety and Efficacy of Dexmedetomidine Compared With Midazolam) Study Group. Dexmedetomidine vs midazolam for sedation of critically ill patients: a randomized trial. JAMA. 2009 Feb 4;301(5):489-99. doi: 10.1001/jama.2009.56. Epub 2009 Feb 2.</citation>
    <PMID>19188334</PMID>
  </results_reference>
  <results_reference>
    <citation>Tan JA, Ho KM. Use of dexmedetomidine as a sedative and analgesic agent in critically ill adult patients: a meta-analysis. Intensive Care Med. 2010 Jun;36(6):926-39. doi: 10.1007/s00134-010-1877-6. Epub 2010 Apr 8. Review.</citation>
    <PMID>20376429</PMID>
  </results_reference>
  <results_reference>
    <citation>Chrysostomou C, Schmitt CG. Dexmedetomidine: sedation, analgesia and beyond. Expert Opin Drug Metab Toxicol. 2008 May;4(5):619-27. doi: 10.1517/17425255.4.5.619 . Review.</citation>
    <PMID>18484919</PMID>
  </results_reference>
  <results_reference>
    <citation>Grosu I, Lavand'homme P. Use of dexmedetomidine for pain control. F1000 Med Rep. 2010 Dec 17;2:90. doi: 10.3410/M2-90.</citation>
    <PMID>21283652</PMID>
  </results_reference>
  <results_reference>
    <citation>Kettner SC, Willschke H, Marhofer P. Does regional anaesthesia really improve outcome? Br J Anaesth. 2011 Dec;107 Suppl 1:i90-5. doi: 10.1093/bja/aer340. Review.</citation>
    <PMID>22156274</PMID>
  </results_reference>
  <results_reference>
    <citation>Shir Y, Raja SN, Frank SM. The effect of epidural versus general anesthesia on postoperative pain and analgesic requirements in patients undergoing radical prostatectomy. Anesthesiology. 1994 Jan;80(1):49-56.</citation>
    <PMID>8291729</PMID>
  </results_reference>
  <results_reference>
    <citation>Huupponen E, Maksimow A, Lapinlampi P, Särkelä M, Saastamoinen A, Snapir A, Scheinin H, Scheinin M, Meriläinen P, Himanen SL, Jääskeläinen S. Electroencephalogram spindle activity during dexmedetomidine sedation and physiological sleep. Acta Anaesthesiol Scand. 2008 Feb;52(2):289-94. Epub 2007 Nov 14.</citation>
    <PMID>18005372</PMID>
  </results_reference>
  <results_reference>
    <citation>Alexopoulou C, Kondili E, Diamantaki E, Psarologakis C, Kokkini S, Bolaki M, Georgopoulos D. Effects of dexmedetomidine on sleep quality in critically ill patients: a pilot study. Anesthesiology. 2014 Oct;121(4):801-7. doi: 10.1097/ALN.0000000000000361.</citation>
    <PMID>24988068</PMID>
  </results_reference>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 10, 2016</study_first_submitted>
  <study_first_submitted_qc>August 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 25, 2016</study_first_posted>
  <last_update_submitted>August 17, 2017</last_update_submitted>
  <last_update_submitted_qc>August 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto de Assistencia Medica ao Servidor Publico Estadual, Sao Paulo</investigator_affiliation>
    <investigator_full_name>João manoel Silva Junior</investigator_full_name>
    <investigator_title>Director, Department of Anesthesiology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Persistent Vegetative State</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Midazolam</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

